New drug combo aims to stop prostate cancer from coming back
NCT ID NCT07444983
First seen Mar 09, 2026 · Last updated May 01, 2026 · Updated 10 times
Summary
This study tests whether adding the drug rezvilutamide to standard hormone therapy after prostate cancer surgery can lower the chance of the cancer returning. About 33 high-risk patients will take the drug daily for up to 2 years. The main goal is to see how many stay cancer-free for 3 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER (ADENOCARCINOMA) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Urology, Fujian Union Hospital, Fujian Medical University
Fuzhou, Fujian, 350000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.